Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine
Abstract The fixed‐dose combination of the direct acting antivirals glecaprevir (GLE) and pibrentasvir (PIB) is an oral, once‐daily treatment for all six major genotypes of chronic hepatitis C virus infection. A single and multiple‐dose rifampin study (N = 12) and a carbamazepine study (N = 12) were...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13471 |